Literature DB >> 18762664

The use of bone morphogenetic protein in lumbar spine surgery.

Jeffrey A Rihn1, Charley Gates, Steven D Glassman, Frank M Phillips, James D Schwender, Todd J Albert.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762664

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


× No keyword cloud information.
  6 in total

Review 1.  Bone grafts, bone substitutes and orthobiologics: the bridge between basic science and clinical advancements in fracture healing.

Authors:  Timothy T Roberts; Andrew J Rosenbaum
Journal:  Organogenesis       Date:  2012-10-01       Impact factor: 2.500

2.  Risk of Cancer Following Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rhBMP-2): An Analysis Using a Commercially Insured Patient Population.

Authors:  Gregory S Cooper; Tzuyung Doug Kou
Journal:  Int J Spine Surg       Date:  2018-08-03

3.  Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2).

Authors:  Gregory S Cooper; Tzuyung Doug Kou
Journal:  Spine (Phila Pa 1976)       Date:  2013-10-01       Impact factor: 3.468

Review 4.  The Use of Bone Grafts, Bone Graft Substitutes, and Orthobiologics for Osseous Healing in Foot and Ankle Surgery.

Authors:  Jonathan R Peterson; Fangyu Chen; Eugene Nwankwo; Travis J Dekker; Samuel B Adams
Journal:  Foot Ankle Orthop       Date:  2019-07-10

5.  Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in posterolateral lumbar spine fusion: complications in the elderly.

Authors:  Martin F Hoffmann; Clifford B Jones; Debra L Sietsema
Journal:  J Orthop Surg Res       Date:  2013-01-14       Impact factor: 2.359

6.  NSAIDS inhibit in vitro MSC chondrogenesis but not osteogenesis: implications for mechanism of bone formation inhibition in man.

Authors:  Ippokratis Pountos; Peter V Giannoudis; Elena Jones; Anne English; Sarah Churchman; Sarah Field; Frederique Ponchel; Howard Bird; Paul Emery; Dennis McGonagle
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.